Site-Specific HDX-MS Achieves Single Amino Acid Resolution, Deeply Characterizing WDR5 Inhibitor Interactions

Conventional Hydrogen-Deuterium eXchange Mass Spectrometry (HDX-MS) is a cornerstone technique in the biopharmaceutical industry, prized for its ability to rapidly identify binding sites and elucidate molecular mechanisms of action for drug candidates. However, a significant limitation of this widely adopted method is its inherently low spatial resolution, typically providing averaged information over segments of five or more amino acids. This lack of precision can obscure subtle, yet critical, dynamic shifts in protein-drug interactions, hindering the rational design and optimization of therapeutics. Improving this resolution is paramount for a deeper understanding of drug binding, particularly for challenging targets such as WDR5, a highly druggable protein implicated in various cancers.

Researchers developed and demonstrated a sensitive, broadly applicable method for single amino acid resolution HDX-MS measurements, termed site-specific HDX-MS. To validate its enhanced capabilities, they applied this novel technique to a set of five distinct therapeutic candidates. These candidates were all designed to target WDR5, a crucial protein involved in cancer pathways. The study meticulously explored the analytical power gained from this site specificity, comparing its insights against those obtained from conventional peptide-level HDX-MS experiments, which typically offer lower resolution. The experimental design focused on revealing how the new method could provide more granular details about drug-protein interactions.

The newly developed site-specific HDX-MS method successfully achieved single amino acid resolution, a substantial improvement over the typical five-amino acid segment resolution of conventional HDX-MS. This unprecedented level of detail revealed dynamic shifts in protein-drug interactions that were previously undetectable. The enhanced analytical power was demonstrated across several critical aspects of drug characterization. For instance, the method enabled highly precise binding mode characterization, offering a granular view of how each therapeutic candidate interacts with WDR5 at specific amino acid residues. It also facilitated accurate affinity ranking among the five WDR5 inhibitors, providing a more reliable measure of their binding strengths.

Crucially, the site-specific HDX-MS method detected molecular features and conformational changes that remained "silent" in conventional peptide-level HDX-MS experiments, highlighting its capacity to uncover subtle yet significant mechanistic details. This breakthrough in resolution provides a deeper, more comprehensive understanding of protein-drug complexes and their dynamic behavior.